下一篇:第一次批准
1Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com.
Drugs
|March 5, 2024
概括
一种新型重组人体TRAIL药物阿波纳明在中国首次获得批准,用于治疗复发性或耐火性多发性髓瘤. 这种向治疗诱导瘤细胞亡,为患者提供了新的治疗选择.
科学领域:
- 在瘤学瘤学.
- 生物技术是生物技术.
- 药理学 药理学是指药理学的学科.
背景情况:
- 多发性骨髓瘤是一种血液性恶性瘤,对于复发或耐药病例的治疗选择有限.
- 瘤亡因子相关的诱导亡的连接体 (TRAIL) 途径是癌症治疗的有希望的标,因为它可以选择性地诱导癌细胞的亡.
- 阿波尼尔明是一种用于癌症治疗的新型重组循环 permuted 人类 TRAIL.
研究的目的:
- 总结一下Aponermin. 的发展里程碑.
- 为了突出Aponermin用于多发性骨髓瘤治疗的首次监管批准.
- 提供Aponermin的作用机制和治疗潜力的概述.
主要方法:
- 阿波纳米因是一种重组蛋白,旨在激活死亡受体4和/或5.
- 该药物触发了细胞内酶级联,导致瘤细胞的亡.
- 临床发展涉及与thalidomide和dexamethasone的联合治疗.
主要成果:
- 阿波涅米因与沙利多米德和德克萨结合使用,于2023年11月在中国首次获得批准.
- 该批准适用于患有复发性或耐火性多发性骨髓瘤的患者,这些患者之前至少接受过两种治疗.
- 这标志着Aponermin的临床应用的一个重要里程碑.
结论:
- 阿波尼明代表了多发性骨髓瘤的新疗法策略.
- 药物诱导亡的能力为癌症治疗提供了有针对性的方法.
- 第一次批准意味着Aponermin有可能解决复发性/耐药性多发性髓瘤的未满足需求.
相关概念视频
Drug Nomenclature
1.7K
During the development of a new pharmaceutical, the manufacturer initially assigns a code name to the drug. Once approved, the drug receives a United States Adopted Name (USAN)—a generic, nonproprietary designation. Upon being listed in the United States Pharmacopeia, this nonproprietary name becomes the drug's official name. Additionally, the manufacturer assigns a proprietary name or trademark, which serves as the brand name under which the drug is marketed. It is worth noting that...
1.7K
First Pass Effect
5.5K
Presystemic elimination, or the first-pass effect, is the metabolism of drugs that reduces their effective concentration at the site of action. Apart from the first-pass effect, the systemic bioavailability of the drug is also reduced by other factors, including incomplete absorption or chemical degradation of drugs.
Depending on the route of administration, drugs can be metabolized in the liver, intestine, lungs, and vasculature. Orally administered drugs are first absorbed through the...
Depending on the route of administration, drugs can be metabolized in the liver, intestine, lungs, and vasculature. Orally administered drugs are first absorbed through the...
5.5K
Preclinical Development: Overview
4.4K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.4K
Preparation of 1° Amines: Hofmann and Curtius Rearrangement Overview
3.2K
In the presence of an aqueous base and a halogen, primary amides can lose the carbonyl (as carbon dioxide) and undergo rearrangement to form primary amines. This reaction, called the Hofmann rearrangement, can produce primary amines (aryl and alkyl) in high yields without contamination by secondary and tertiary amines.
3.2K
Adrenergic Receptors: ɑ Subtype
1.5K
Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
1.5K
Drug Metabolism: Phase I Reactions
3.3K
A phase I reaction is a biochemical process that introduces a functionally reactive polar group to a substance. This transformation predominantly occurs in the liver, facilitated by the cytochrome P450 system of hemoproteins situated in the lipophilic endoplasmic reticulum of cells. The metabolite generated through this process can have varying polarities. If it is sufficiently polar, it can be easily excreted in the urine due to its water compatibility. However, if the metabolite is nonpolar,...
3.3K


